A phase III, randomized, double-blind, multi-center study of the efficacy of Taxotere (docetaxel) in combination with Aptosyn (exisulind) versus Taxotere (docetaxel) and placebo in non-small cell lung cancer (NSCLC) patients after failure of prior platinum-based chemotherapy

Trial Profile

A phase III, randomized, double-blind, multi-center study of the efficacy of Taxotere (docetaxel) in combination with Aptosyn (exisulind) versus Taxotere (docetaxel) and placebo in non-small cell lung cancer (NSCLC) patients after failure of prior platinum-based chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2005

At a glance

  • Drugs Docetaxel; Exisulind
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 17 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top